By Dakota Antelman, Managing Editor
MARLBOROUGH – Marlborough-based Capaccio Environmental Engineering announced earlier this month that it has recently helped key COVID-19 vaccine manufacturers scale up their production processes.
Capaccio regularly provides consulting services to any number of companies. Through its vaccine work, though, the company has specifically helped build infrastructure to accelerate the manufacturing of new vaccine doses, according to a press release.
“We’re proud to partner with these companies on this significant undertaking,” said Capaccio CEO Lisa F. Wilk, P.E.. “The work they do is vital, and we are honored to work with them to help them get this vaccine – and future life-saving medicines – out to as many people as quickly and as safely as possible.”
Vaccine production efficiency was a topic of discussion in public health circles even before the Pfizer/BioNTech vaccine became the first such vaccine approved for emergency use in the US late last year.
Shortages then slowed early rollout efforts earlier this year.
While those shortages have eased in Massachusetts and much of the rest of the country, they continue to pose problems elsewhere in the world.
Through this, Capaccio is not the first Marlborough company to lend a hand in the coronavirus fight.
Last year, in the early stages of the pandemic, Marlborough-based Hologic was one of several companies around the country that quickly developed and secured approval for various COVID-19 tests.
“The speed at which this assay was developed, validated and issued EUA—less than two months—is a testament to Hologic’s commitment to helping reduce the global COVID-19 burden,” Rick Bright, director of the federal Biomedical Advanced Research and Development Authority, said in a press release.